Ahead of the Pharmapack Europe we at EPM HQ caught up with Windgap Medical, a start-up pioneering several drug delivery innovations, including a proprietary two-chamber autoinjector that hopes to solve many of the present formulation challenges.
As we move into 2024, life sciences real estate managers will need to consider sustainability, funding, investor consolidation, and planning regulations as top priorities.
Shionogi B.V., the European subsidiary of SHIONOGI & Co., Ltd. have announced that they have signed a distribution agreement with Swedish Orphan Biovitrum AB, Sobi, for Fetcroja covering 13 countries in Central & Eastern Europe.
As we close off this year at EPM, we look back at one of our standout interviews with Alison Dillon, Director of Marketing Communications and Strategy at Sharp.
Organon have announced an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe.
To better understand SGD Pharma and their plans for the future, we at EPM HQ sat down with Olivier Rousseau, CEO of SGD Pharma, for a quick discussion.
Typically, Q&A’s are focused on a single topic or a single individual. To keep things interesting, here at EPM HQ, we devised a range of questions to put towards a varied group of subject matter experts at Lonza. Here’s what they had to say…
Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena looks at how ADCs are being integrated with the capacity to modulate the immune system and how this marks a progressive shift in the fight against cancer.
Signal detection in post-market drug monitoring has changed little in 70 years, but now that shake-up is coming in the form of advanced AI technology combined with democratised access to standardised real-world data, Elizabeth Smalley explores.
In this article, Dr Julian Northen, Solid State Manager at Onyx Scientific, explores the challenges associated with achieving sustainability in pharma and the solutions the industry must adopt to ensure alignment with global goals and regulations.
Josh Ludwig, Global Commercial Director, ScaleReady explores the necessity of simplifying cell and gene therapy in order to successfully integrate artificial intelligence and automation technologies in our latest EPM insight.
